Zevra Therapeutics Inc. (ZVRA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $11.61 (-1.94%), Market cap $0.62B, P/E ratio 5.22, 52-week low–high $7.23 ~ $12.79.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactiv
Financial statements, price targets, institutional (13F) holdings and related news for Zevra Therapeutics Inc. are updated in real time on BlackAll Trade.
Zevra Therapeutics Inc. trades at $11.61 (-1.94%). Real-time quotes and charts are available on BlackAll Trade.
Zevra Therapeutics Inc. has a market cap of about $0.62B. Its P/E ratio is 5.22.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activa